Most Active
Lexeo Therapeutics Surges 47% After LX2020 Gene Therapy Cuts Dangerous Heart Arrhythmias by Up to 80%
Read this in the Market Flux appLexeo Therapeutics, Inc. Common Stock $LXEO
$3.23+12.72%as of publication
- 5D Change
- +2.70%
- Notional
- $119.92M
Lexeo Therapeutics reported positive interim data from its HEROIC-PKP2 Phase I/II trial of LX2020, a gene therapy targeting PKP2 arrhythmogenic cardiomyopathy, a rare and potentially fatal inherited heart condition. The high-dose cohort showed an 80% reduction in non-sustained ventricular tachycardia and a 44% reduction in premature ventricular contractions, two of the most clinically significant arrhythmia endpoints in PKP2-ACM.
The market responded sharply, with LXEO shares gapping up 46.6% at the open on November 16, reflecting investor confidence in the strength of the interim readout. Pre-market indications had the stock up roughly 23.7% before trading began, underscoring the significance of the data relative to expectations.
© AI-generated summary is provided by Market Flux
Sources
- BioStocks$LXEO announces positive interim data from the HEROIC-PKP2 Phase I/II trial of LX2020 for the treatment of PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM)
- BriefingcomGapping up: $LXEO +46.6% $OCS +12.9% $DRTS +10.6% $IDYA +6.6% $ZYME +3.7% Gapping down: $HELP -26.8% $SMMT -13.8% $POET -8.7% $WULF -5.2%
- OpenOutcrier$LXEO (+23.7% pre) Lexeo reports interim trial results for PKP2-ACM gene therapy
- BPharmCatalyst$HELP announced positive Phase 3 APPROACH data for HLP003 (deuterated psilocin) as an adjunct in major depressive disorder (n=222). The trial met its primary endpoint with a 7.6-point placebo-adjusted MADRS reduction at Week 6 (p<0.0001), sustained at 7.0 points through Week 12. Week 6 response and remission rates were 56.3% and 50.9% versus 28.2% and 18.2% for placebo, with onset by Day 2. Three treatment-related SAEs occurred; Phase 3 EMBRACE results are expected in Q4 2027. $ACRS $LXEO $CRDF $OCS $HELP $DRTS $AKAN $INAB $XRTX $ADXN See More Pre-market Movers at BioPharmCatalyst in the Articles Menu